Speclipse, Inc.

Speclipse, Inc. is a pioneering medical device developer that specializes in skin cancer diagnostic solutions. Using laser-induced plasma spectroscopy (LIPS) and artificial intelligence (AI) technology, the company has created Spectra-Scope®, the world's first real-time, non-invasive, in-vivo diagnosis of skin cancers. This innovation aims to improve accuracy in diagnosis while minimizing the need for unnecessary biopsies. Since its establishment in 2015, Speclipse, Inc. has been dedicated to providing cutting-edge medical technology to support physicians in challenging diagnostic cases. The company's headquarter is located in the United States, with a focus on the Biotechnology and Health Care sectors. Despite the absence of publicly disclosed information about recent investments, Speclipse, Inc. continues to be a prominent player in the advancement of skin cancer diagnostic solutions with its commitment to innovation and technological improvement.